A blood gene expression marker of early Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 33, Issue 3, 2013, Pages 737-753

  Lunnon, Katie ^a,b   Sattlecker, Martina ^a,b   Furney, Simon J ^a,b,i   Coppola, Giovanni ^c   Simmons, Andrew ^a,b   Proitsi, Petroula ^a   Lupton, Michelle K ^a   Lourdusamy, Anbarasu ^a,b   Johnston, Caroline ^b   Soininen, Hilkka ^d   Kłoszewska, Iwona ^e   Mecocci, Patrizia ^f   Tsolaki, Magda ^g   Vellas, Bruno ^h   Geschwind, Daniel ^c   Lovestone, Simon ^a,b   Dobson, Richard ^a,b   Hodges, Angela ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f UNIVERSITY OF PERUGIA   (Italy)

^g ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^h UNIVERSITÉ DE TOULOUSE   (France)

ⁱ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Alzheimer's disease; biomarkers; blood; diagnosis; gene expression pattern analysis; leukocytes; magnetic resonance imaging; mild cognitive impairment

Indexed keywords

ACCURACY; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GENE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTOR VARIABLE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 84872437471     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-121363     Document Type: Article

References (104)

1. Prince M, Jackson J (2009) Alzheimer's Disease International World Alzheimer Report. Alzheimer's Disease International, http://www.alz.co.uk/ research/files/WorldAlzheimerReport.pdf
2. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P (2010) Revising the definition of Alzheimer's disease: A new lexicon. Lancet Neurol 9, 1118-1127.
3. Cummings JL (2010) Integrating ADNI results into Alzheimer's disease drug development programs. Neurobiol Aging 31, 1481-1492.
4. Lovestone S, Thambisetty M (2009) Biomarkers for Alzheimer's disease trials - biomarkers for what? A discussion paper. J Nutr Health Aging 13, 334-336.
5. SampaioC(2009) Biomarkers in clinical trials of Alzheimer Disease (AD): What is expected from regulatory agencies? J Nutr Health Aging 13, 339-340.
6. Furiak N, Klein R, Kahle-Wrobleski K, Siemers E, Sarpong E, Klein T (2010) Modeling screening, prevention, and delaying of Alzheimer's disease: An early-stage decision analytic model. BMC Med Inf Decis Making 10, article 24, 1-24.
7. Bancher C, Braak H, Fischer P, Jellinger KA (1993) Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci Lett 162, 179-182. (Pubitemid 23347976)
8. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 82, 239-259.
9. Amieva H, Le Goff M, Millet X, Orgogozo JM, Peres K, Barberger-Gateau P, Jacqmin-Gadda H, Dartigues JF (2008) Prodromal Alzheimer's disease: Successive emergence of the clinical symptoms. Ann Neurol 64, 492-498.
10. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403. (Pubitemid 44108123)
11. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
12. Jack CR, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS (2011) Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 68, 1526-1535.
13. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC,McKeelDW, FarlowM,Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, Decarli C, Leight S, Lee VMY, Trojanowski JQ (2003) Cerebrospinal fluid tau and beta-amyloid - How well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60, 1696-1702. (Pubitemid 37521622)
14. Strozyk D, Blennow K, White LR, Launer LJ (2003) CSF A beta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60, 652-656. (Pubitemid 36246085)
15. Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O (2010) Evaluation of CSF biomarkers as predictors of Alzheimer's disease:Aclinical follow-up study of 4.7 years. J Alzheimers Dis 21, 1119-1128.
16. Schoonenboom NSM, van der Flier WM, Blankenstein MA, Bouwman FH,Van Kamp GJ, Barkhof F, Scheltens P (2008) CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiol Aging 29, 669-675. (Pubitemid 351400823)
17. Fagan AM (2006) Inverse relation between in vivo amyloid imaging load and CSF A[beta]42 in humans. Ann Neurol 59, 512-519. (Pubitemid 43358072)
18. Grimmer T, Riemenschneider M, Forstl H, Henriksen G, KlunkWE,Mathis CA, ShigaT,Wester HJ,Kurz A, Drzezga A (2009) Beta amyloid in Alzheimer's disease: Increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 65, 927-934.
19. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, Foster NL, Petersen RC, Weiner MW, Price JC, Mathis CA (2009) Relationships between biomarkers in aging and dementia. Neurology 73, 1193-1199.
20. Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, Windhorst AD, Scheltens P, Lammertsma AA, van BerckelBNM(2009) Relationship of cerebrospinal fluid markers to C-11-PiB and F-18-FDDNP binding. J Nucl Med 50, 1464-1470.
21. Thambisetty M, Lovestone S (2010) Blood-based biomarkers of Alzheimer's disease: Challenging but feasible. Biomark Med 4, 65-79.
22. Buerger K, Ernst A, Ewers M, Uspenskaya O, Omerovic M, Morgenthaler NG, Knauer K, Bergmann A, Hampel H (2009) Blood-based microcirculation markers in Alzheimer's disease-diagnostic value of midregional pro-atrial natriuretic peptide/C-terminal endothelin-1 precursor fragment ratio. Biol Psychiatry 65, 979-984.
23. Hye A (2006) Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129, 3042-3050. (Pubitemid 44684524)
24. Hye A, Kerr F, Archer N, Foy C, Poppe M, Brown R, Hamilton G, Powell J, Anderton B, Lovestone S (2005) Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci Lett 373, 1-4. (Pubitemid 39536210)
25. O'Bryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, Waring S, az-Arrastia R (2010) A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 67, 1077-1081.
26. O'Bryant SE, Xiao G, Barber R, Reisch J, Hall J, Cullum C, Doody R, Fairchild T, Adams P, Wilhelmsen K, az-Arrastia R (2011) A blood-based algorithm for the detection of Alzheimer's disease. Dement Geriatr Cogn Disord 32, 55-62.
27. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks D, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13, 1359-1362. (Pubitemid 350073592)
28. Schneider P, Hampel H, BuergerK(2009) Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Therap 15, 358-374.
29. Thambisetty M, Hye A, Foy C, Daly E, Glover A, Cooper A, Simmons A, Murphy D, Lovestone S (2008) Proteomebased identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J Neurol 255, 1712-1720.
30. Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, Wahlund L, Estman E, Kinsey A, Guentert A, Proitsi P, Causevic M, Killick R, Lunnon K, Lynham S, Broadstock M, Choudhry F, Howlett D, Williams R, Sharp S, Mitchelmore C, Tunnard C, Leung R, Foy C, O'Brien D, Breen G, Furney S, Kloszewska I, Mecocci P, Soinenen M, Tsolaki B, Vellas B, Hodges A, Murphy D, Parkins S, Richardson J, Ferucci L, Wong D, Zhou Y, Muehlboeck S, Evans A, Francis P, Spenger C, Lovestone S (2010) Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 67, 739-748.
31. Booij BB, Lindahl T, Wetterberg P, Skaane NV, Sæbø S, Feten G, Rye PD, Kristiansen LI, Hagen N, Jensen M, B°ardsen K, Winblad B, Sharma P, Lonneborg A (2011) A gene expression pattern in blood for the early detection of Alzheimer's disease. J Alzheimers Dis 23, 109-119.
32. Rye PD, Booij BB, Grave G, Lindahl T, Kristiansen L, Andersen HM, Horndalsveen PO, Nygaard HA, Naik M, Hoprekstad D,Wetterberg P, Nilsson C, Aarsland D, Sharma P, Lonneborg A (2011) A novel blood test for the early detection of Alzheimer's disease. J Alzheimers Dis 23, 121-129.
33. Fehlbaum-Beurdeley P, Prado ACJL, Pallares D, Carriere J, Soucaille C, Rouet F, Drouin D, Sol O, Jordan H, Wu DR, Lei L, Einstein R, Schweighoffer F, Bracco L (2010) Toward an Alzheimer's disease diagnosis via high-resolution blood gene expression. Alzheimers Dement 6, 25-38.
34. Westman E, Simmons A, Muehlboeck JS, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H,WeinerMW, Lovestone S, Spenger C, Wahlund LO (2011) AddNeuroMed and ADNI: Similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. NeuroImage 58, 818-828.
35. Fan Y, Batmanghelich N, Clark CM, Davatzikos C (2008) Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline. NeuroImage 39, 1731-1743. (Pubitemid 351179414)
36. Westman E, Simmons A, ZhangY, Muehlboeck JS, Tunnard C, Liu Y, Collins L, Evans A, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H, Lovestone S, Spenger C, Wahlund LO (2011) Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. NeuroImage 54, 1178-1187.
37. Jack CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 257-262.
38. Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, Tangalos EG, Boeve BF, Knopman DS, Braak H, Petersen RC (2006) Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 63, 674-681.
39. Mitchell AJ, Shiri-Feshki M (2009) Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 119, 252-265.
40. Saxton J, Snitz BE, Lopez OL, Ives DG, Dunn LO, Fitzpatrick A (2009) Functional and cognitive criteria produce different rates of MCI. J Neurol Neurosurg Psychiatry 80, 737-743.
41. Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, Barnes LL, Fox JH, Bach J (2002) Natural history of mild cognitive impairment in older persons. Neurology 59, 198-205. (Pubitemid 34779177)
42. Decarli C (2003) Mild cognitive impairment: Prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2, 15-21.
43. Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS (2005) Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 64, 834-841. (Pubitemid 40316322)
44. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, Smith GE, Jack CR (2009) Mild cognitive impairment ten years later. Arch Neurol 66, 1447-1455.
45. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA (2009) The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 66, 200-208.
46. Lovestone S, Francis P, Strandgaard K, AddNeuroMed CG (2007) Biomarkers for disease modification trials - The innovative medicines initiative and AddNeuroMed. J Nutr Health Aging 11, 359-361. (Pubitemid 47121941)
47. Lovestone S, Francis P, Kloszewska I, Mecocci P, Simmons A, Soininen H, Spenger C, Tsolaki M, Vellas B, Wahlund L,Ward M (2009) AddNeuroMed-the European collaboration for the discovery of novel biomarkers for Alzheimer's disease. Ann N Y Acad Sci 1180, 36-46.
48. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO (1983) Development and validation of a geriatric depression screening scale - a preliminary-report. J Psychiatr Res 17, 37-49.
49. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of theNINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944. (Pubitemid 14076461)
50. American Psychiatric Association. 2000 IV-TR), 4th edition. Washington, DC.
51. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders (IV-TR), 4th edition. Washington, DC. [51] Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56, 303-308. (Pubitemid 29120227)
52. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L,Winblad B (2001) Current concepts in mild cognitive impairment. Arch Neurol 58, 1985-1992. (Pubitemid 33143977)
53. Morris JC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43, 2412-2414. (Pubitemid 23346995)
54. Foy CML, Nicholas H, Hollingworth P, Boothby H,Willams J, Brown RG, Al-Sarraj S, Lovestone S (2007) Diagnosing Alzheimer's disease - non-clinicians and computerised algorithms together are as accurate as the best clinical practice. Int J Geriatr Psychiatry 22, 1154-1163. (Pubitemid 350120666)
55. Folstein MF, Folstein SE, McHugh PR (1975) Mini-Mental State - practical method for grading cognitive state of patients for clinician. J Psychiatr Res 12, 189-198.
56. Reisberg B, Ferris SH, Deleon MJ, Crook T (1988) Global Deterioration Scale (GDS). Psychopharmacol Bull 24, 661-663.
57. Welsh K, Butters N, Hughes J, Mohs R, Heyman A (1991) Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures. Arch Neurol 48, 278-281.
58. Du P, Kibbe WA, Lin SM (2008) lumi: A pipeline for processing Illumina microarray. Bioinformatics 24, 1547-1548. (Pubitemid 351911712)
59. Simmons A, Westrnan E, Muehlboeck S, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Wahlund LO, Soininen H, Lovestone S, Evans A, Spenger C, AddNeuroMed C (2009) MRI measures of Alzheimer's disease and the AddNeuroMed Study. Biomarkers Brain Dis 1180, 47-55.
60. Simmons A, Westman E, Muehlboeck S, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Wahlund LO, Soininen H, Lovestone S, Evans A, Spenger C (2011) The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: Experience from the first 24 months. Int J Geriatr Psychiatry 26, 75-82.
61. Shi L, Campbell G, Jones WD, Campagne F,Wen Z,Walker SJ, Su Z, Chu TM, Goodsaid FM, Pusztai L, Shaughnessy JD, Oberthuer A, Thomas RS, Paules RS, Fielden M, Barlogie B, ChenW, Du P, Fischer M, Furlanello C, Gallas BD, Ge X, Megherbi DB, SymmansW,Wang MD, Zhang J, Bitter H, Brors B, Bushel PR, Bylesjo M, Chen M, Cheng J, Cheng J, Chou J, Davison TS, Delorenzi M, Deng Y, Devanarayan V, Dix DJ, Dopazo J, Dorff KC, Elloumi F, Fan J, Fan S, Fan X, Fang H, Gonzaludo N, Hess KR, Hong H, Huan J, Irizarry RA, Judson R, Juraeva D, Lababidi S, Lambert CG, Li L, Li Y, Li Z, Lin SM, Liu G, Lobenhofer EK, Luo J, Luo W. (2010) The MicroArray Quality Control (MAQC)-IIII study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 28, 827-838.
62. Schwarz DF, Knig IR, ZieglerA(2010) On safari to Random Jungle: A fast implementation of Random Forests for highdimensional data. Bioinformatics 26, 1752-1758.
63. Meng Y, Yu Y, Cupples LA, Farrer L, Lunetta K (2009) Performance of random forest when SNPs are in linkage disequilibrium. BMC Bioinformatics 10, 78.
64. Blennow K (2004) Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 1, 213-225. (Pubitemid 46589353)
65. Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Andreasson U, Zetterberg H, Blennow K, Svensson J (2011) Cerebrospinal fluid biomarkers for Alzheimer's disease: Diagnostic performance in a homogeneous monocenter population. J Alzheimers Dis 24, 537-546.
66. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroeder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilae T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. J Am Med Assoc 302, 385-393.
67. Rabinovici GD, JagustWJ(2009) Amyloid imaging in aging and dementia: Testing the amyloid hypothesis in vivo. Behav Neurol 21, 117-128.
68. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L,Wallin AK, Hampel H, Burger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009) Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol 8, 619-627.
69. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi WZ, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65, 1509-1517.
70. Bouwman FH, Schoonenboom NSM, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, Scheltens P, van der Flier WM (2009) CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol Aging 30, 1895-1901.
71. Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, Trojanowski JQ, Blennow K (2010) Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol 223, 334-346.
72. Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L (2007) Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 23, 316-320. (Pubitemid 46631938)
73. Mintun MA (2006) [11C] PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 67, 446-452. (Pubitemid 44214969)
74. Peskind ER, Li G, Shofer J, Quinn JF, Kaye JA, Clark CM, Farlow MR, Decarli C, Raskind MA, Schellenberg GD, Lee VMY, Galasko DR (2006) Age and apolipoprotein E.4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol 63, 936-939. (Pubitemid 44036292)
75. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
76. Lunnon K, Ibrahim Z, Proitsi P, Lourdusamy A, Newhouse S, Sattlecker M, Furney S, Saleem M, Soinenen M, Kloszewska I, Mecocci P, Tsolaki B, Vellas B, Coppola G, Geschwind DH, Simmons A, Lovestone S, Dobson R, Hodges A, on behalf of the AddNeuroMed C (2012) Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease blood. J Alzheimers Dis 30, 685-710.
77. Ankarcrona M, Mangialasche F,Winblad B (2010) Rethinking Alzheimer's disease therapy: Are mitochondria the key? J Alzheimers Dis 20, S579-S590.
78. Manczak M, Park BS, Lung YS, Reddy PH (2004) Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease - Implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Med 5, 147-162. (Pubitemid 38596548)
79. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH (2006) Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: Implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15, 1437-1449.
80. RheinV, SongXM,Wiesner A, Ittner LM, Baysang G, Meier F, Ozmen L, Bluethmann H, Drose S, Brandt U, Savaskan E, Czech C, Gotz J, EckertA(2009) Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A 106, 20057-20062.
81. Fox NC, Scahill RI, Crum WR, Rossor MN (1999) Correlation between rates of brain atrophy and cognitive decline in AD. Neurology 52, 1687-1689. (Pubitemid 29220648)
82. Jack CR, Petersen RC, Obrien PC, Tangalos EG (1992) MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology 42, 183-188.
83. Frisoni GB, Fox NC, Jack CR, Scheltens P, Thompson PM (2010) The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 6, 67-77.
84. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T (2009) Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66, 382-389.
85. Wahlund LO, Blennow K (2003) Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 339, 99-102. (Pubitemid 36254786)
86. Caroli A, Frisoni GB (2010) The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. Neurobiol Aging 31, 1263-1274.
87. Diniz BSO, Pinto JA, Forlenza OV (2008) Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry 9, 172-182.
88. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr, Alzheimer's Disease Neuroimaging, Initiative (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: Diagnostic discrimination and cognitive correlations. Neurology 73, 287-293.
89. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr, Alzheimer's Disease Neuroimaging, Initiative (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change. Neurology 73, 294-301.
90. Bruscoli M, Lovestone S (2004) Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr 16, 129-140. (Pubitemid 38963102)
91. Maes OC, Xu S, Yu B, Chertkow HM, Wang E, Schipper HM (2007) Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol Aging 28, 1795-1809. (Pubitemid 47539691)
92. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
93. Angelopoulos P, Agouridaki H, Vaiopoulos H, Siskou E, Doutsou K, Costa V, Baloyiannis SI (2008) Cytokines in Alzheimer's disease and vascular dementia. Int J Neurosci 118, 1659-1672.
94. Baranowska-Bik A, Bik W, Wolinska-Witort E, Martynska L, Chmielowska M, Barcikowska M, Baranowska B (2008) Plasma beta amyloid and cytokine profile in women with Alzheimer's disease. Neuroendocrinol Lett 29, 75-79.
95. Bermejo P, Martin-Aragon S, Benedi J, Susin C, Felici E, Gil P, Ribera JM, Villar AM (2008) Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from mild cognitive impairment. Free Radic Res 42, 162-170. (Pubitemid 351298365)
96. Bermejo P, Martin-Aragon S, Benedi J, Susin C, Felici E, Gil P, Ribera JM, Villar AM (2008) Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunol Lett 117, 198-202.
97. Desideri G, Cipollone F, Necozione S, Marini C, Lechiara MC, Taglieri G, Zuliani G, Fellin R, Mezzetti A, Di Orio F, Ferri C (2008) Enhanced soluble CD40 ligand and Alzheimer's disease: Evidence of a possible pathogenetic role. Neurobiol Aging 29, 348-356. (Pubitemid 351215586)
98. Dik MG, Jonker C, Hack CE, Smit JH, Comijs HC, Eikelenboom P (2005) Serum inflammatory proteins and cognitive decline in older persons. Neurology 64, 1371-1377. (Pubitemid 40570504)
99. Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, Stijnen T, Hofman A, Witteman JCM, Breteler MMB (2004) Inflammatory proteins in plasma and the risk of dementia - The Rotterdam study. Arch Neurol 61, 668-672. (Pubitemid 38637682)
100. Mocali A, Cedrola S, la Malva N, Bontempelli M, Mitidieri VAM, Bavazzano A, Comolli R, Paoletti F, La Porta CAM (2004) Increased plasma levels of soluble CD40, together with the decrease of TGF beta 1, as possible differential markers of Alzheimer disease. Exp Gerontol 39, 1555-1561. (Pubitemid 39410556)
101. Schuitemaker A, Dik MG, Veerhuis R, Scheltens P, Schoonenboom NSM, Hack CE, Blankenstein MA, Jonker C (2009) Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol Aging 30, 1885-1889.
102. Coppola G, Karyda A, Rademakers R, Wang Q, Baker M, Hutton M, Miller BL, Geschwind DH (2008) Gene expression study on peripheral blood identifies progranulin mutations. Ann Neurol 64, 92-96.
103. Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N (2010) A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 68, 930-941.
104. van Rossum IA, Vos S, Handels R, Visser PJ (2010) Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: Implications for trial design. J Alzheimers Dis 20, 881-891.